KR20090109007A - Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same - Google Patents
Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same Download PDFInfo
- Publication number
- KR20090109007A KR20090109007A KR1020080034386A KR20080034386A KR20090109007A KR 20090109007 A KR20090109007 A KR 20090109007A KR 1020080034386 A KR1020080034386 A KR 1020080034386A KR 20080034386 A KR20080034386 A KR 20080034386A KR 20090109007 A KR20090109007 A KR 20090109007A
- Authority
- KR
- South Korea
- Prior art keywords
- caffeic acid
- extract
- javanica
- liver
- ethanol
- Prior art date
Links
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 title claims abstract description 110
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 229940074360 caffeic acid Drugs 0.000 title claims abstract description 55
- 235000004883 caffeic acid Nutrition 0.000 title claims abstract description 55
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000000469 ethanolic extract Substances 0.000 title claims description 9
- 230000002443 hepatoprotective effect Effects 0.000 title claims description 4
- 239000000284 extract Substances 0.000 claims abstract description 28
- 240000008881 Oenanthe javanica Species 0.000 claims abstract description 16
- 235000000365 Oenanthe javanica Nutrition 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003960 organic solvent Substances 0.000 claims abstract 3
- 239000000706 filtrate Substances 0.000 claims abstract 2
- 238000001914 filtration Methods 0.000 claims abstract 2
- 238000004108 freeze drying Methods 0.000 claims abstract 2
- 206010067125 Liver injury Diseases 0.000 claims description 24
- 231100000234 hepatic damage Toxicity 0.000 claims description 24
- 230000008818 liver damage Effects 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 10
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 9
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 9
- 238000004007 reversed phase HPLC Methods 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 5
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 4
- 241000212324 Oenanthe <angiosperm> Species 0.000 claims description 2
- 235000005324 Typha latifolia Nutrition 0.000 claims description 2
- 244000118869 coast club rush Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000011140 membrane chromatography Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 244000088415 Raphanus sativus Species 0.000 claims 2
- 238000002481 ethanol extraction Methods 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 1
- 238000011210 chromatographic step Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 229940093499 ethyl acetate Drugs 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 11
- 239000012141 concentrate Substances 0.000 abstract description 2
- 238000007598 dipping method Methods 0.000 abstract 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 26
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 13
- 239000002285 corn oil Substances 0.000 description 8
- 235000005687 corn oil Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000220259 Raphanus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 240000006240 Linum usitatissimum Species 0.000 description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 240000009164 Petroselinum crispum Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000061 acid fraction Substances 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 235000011197 perejil Nutrition 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000218206 Ranunculus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000002036 chloroform fraction Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- -1 lipid peroxides Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BVDPFTQTMQKPGQ-UHFFFAOYSA-N ethanol hydrofluoride Chemical compound F.CCO BVDPFTQTMQKPGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/26—Food, ingredients or supplements targeted to meet non-medical requirements, e.g. environmental, religious
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 불미나리(Oenanthe javanica DC)에서 카페익산을 추출하는 방법 및 이를 포함하는 기능성 건강식품에 관한 것으로, 더욱 상세하게는 불미나리에서 간세포 보호 및 간 손상 예방 효능이 있는 분리한 카페익산을 추출하는 방법 및 이를 포함하는 기능성 건강지향식품에 관한 것이다.The present invention relates to a method for extracting caffeic acid from Oenanthe javanica DC and to a functional health food comprising the same, and more particularly, to a method for extracting isolated caffeic acid, which is effective in protecting liver cells and preventing liver damage from the light parsley. And it relates to a functional health-oriented food comprising the same.
간은 외부에서 들어온 생체 외 물질로부터 전신을 방어하는 기능을 수행하고 있으며, 건강에 유익한 영양분뿐만 아니라 독성물질에 노출될 위험이 다른 장기보다 많아 손상될 확률도 매우 높다. 간은 재생이 우수한 장기이나, 손상이 지속될 경우 간 조직의 일부가 완전히 파괴되고, 그 기능이 저하되어 정상 간으로서의 기능을 발휘하기 어려운 상태가 되며, 이와 관련된 질환은 간섬유화, 간경화, 간암 등이 있다. 이러한 만성적 간질환은 질환으로써 발병되기 전에 자각증상이 없는 경우가 대부분으로, 간 손상 정도가 심한 정도가 되어야 자각증상이 나타나고 치료가 이루어지므로 그 치료와 완치가 매우 어렵다. 이에 간에 부담을 주지 않은 안전성을 가지면서, 간 손상 만성화를 미리 예방할 수 있는 간세포 및 간 손상 예방 기능성 소재를 찾고자 하는 노력이 필요하다. The liver functions to protect the whole body from in vitro exogenous substances, and the risk of exposure to other toxic substances as well as nutrients that are beneficial to health is higher than that of other organs. The liver is a long-term excellent regeneration, but if the damage is sustained, part of the liver tissue is completely destroyed, the function is degraded, it becomes difficult to function as a normal liver, and related diseases include liver fibrosis, cirrhosis, liver cancer, etc. have. Most of these chronic liver diseases are asymptomatically before the onset of symptoms, and most of the damage to the degree of liver damage is a symptomatic symptom and the treatment is so difficult to treat and cure. Accordingly, efforts to find a functional material capable of preventing liver cells and liver damage that can prevent chronic liver damage in advance while having safety without burdening the liver are necessary.
사염화탄소(CCl4)는 간에 손상을 주는 표본물질로서 마우스와 같은 설치류에 직접 투여하는 방법을 이용하여 주로 간 손상을 유발시켜 연구하는데 널리 이용된다. 사염화탄소(CCl4)는 사이토크롬 P450과 같은 대사효소에 의해 반응하여 자유라디칼인 CCl3가 생성되면 이는 간의 중성지방과 막인지질의 산화를 유발하며, 이는 산소와 결합하여 지질 과산화물을 형성한다. 또한 이러한 과산화물에 의해 간에 여러 기능들이 파괴되어 간조직의 손상을 유발하게 된다(Chang. J. M. et. al., Drug and chemical toxicology, 6. 443-453, 1983).Carbon tetrachloride (CCl 4 ) is a sample that damages the liver, and is widely used to study liver damage mainly by direct administration to rodents such as mice. When carbon tetrachloride (CCl 4 ) is reacted by a metabolic enzyme such as cytochrome P 450 to produce the free radical CCl 3 , it causes oxidation of hepatic triglycerides and membrane phospholipids, which combine with oxygen to form lipid peroxides. In addition, these peroxides destroy several functions of the liver and cause damage to liver tissue (Chang. JM et. Al., Drug and chemical toxicology, 6. 443-453, 1983).
불미나리는 미나리속인 다년생 초본으로써 민간에 널리 재배되어 식품으로 주로 이용되고 있으며, 그 잎과 줄기는 한방에서 혈압강하, 해열, 이뇨, 보혈, 지혈, 강장, 주독 및 폐렴의 치료로 이용되는 약용식물의 하나이다(중약대사전, 상해과학기술 출판사, p1332-1333, 1981, 약품식물학각론, 진명출판사, p306, 1980).Flax is a perennial herb that is a genus of perennial herb, widely cultivated and used mainly in food, and its leaves and stems are medicinal plants used for the treatment of blood pressure drop, fever, diuresis, blood, hemostasis, tonic, poison and pneumonia in oriental medicine. It is one (Chinese Medicine Dictionary, Shanghai Science and Technology Press, p1332-1333, 1981, Ph.D., Plant Physics, Jinmyung Publisher, p306, 1980).
미나리 메탄올 추출물은 토끼에서 사염화탄소 투여로 유발된 간기능 손상에 완화효과가 있는 것으로 보고된 바 있었으며(서화중 등, J. Korean Soc. Food Nur., 14, 72-76, 1985), 미나리 부탄올 분획물은 마우스에서 사염화탄소로 유발된 급성 간조직 손상의 예방 효과를 나타낸 바 있다(Lee, S.I. et. al., J. Korean Soc. Food Nur., 22, 392-397, 1993). 또한 같은 미나리과의 파슬리 추출물도 간손상 예방 치료활성이 특허화 된 바 있다(공개특허 2002-0090248호).Buttercup methanol extract has been reported to have a mitigating effect on liver function damage caused by carbon tetrachloride in rabbits (Seohwajung et al., J. Korean Soc. Food Nur., 14, 72-76, 1985). It has been shown to prevent carbon tetrachloride-induced acute liver tissue damage (Lee, SI et. Al., J. Korean Soc. Food Nur., 22, 392-397, 1993). In addition, parsley extracts of the same apiaceae have been patented for the prevention and treatment of liver damage (published patent 2002-0090248).
벌꿀 프로폴리스 추출물의 활성 성분의 하나인 카페익산은 항균, 항염, 항암의 특성으로써 민간 약재로 사용되어졌고(Banskota et al., Phytotherapy Research, 15, 561-571, 2001: Ozen et al., Journal of Applied Toxicology, 23, 27-35, 2004), 지질과산화 억제 및 항산화 효소의 활성을 자극하는 약물학적으로 안전한 성분으로 보고되었다(Zhao, W.X. et al., World Journal of Gastroenterology 9, 1278-1281, 2003).Caffeic acid, one of the active ingredients of honey propolis extract, has been used as a medicinal herb as an antibacterial, anti-inflammatory, and anticancer agent (Banskota et al., Phytotherapy Research, 15, 561-571, 2001: Ozen et al., Journal of Applied Toxicology, 23, 27-35, 2004), reported as a pharmacologically safe ingredient that stimulates lipid peroxidation inhibition and antioxidant enzyme activity (Zhao, WX et al., World Journal of Gastroenterology 9, 1278-1281, 2003).
지금까지 알려진 간세포 보호 및 간손상 예방 효능을 갖는 기능성 식품 소재는 극히 제한적인 것으로, 최근의 건강지향적인 최근의 추세에 따라, 식품소재로부터 상기 효능을 갖는 활성 물질에 대한 발굴의 필요성이 대두되었다. The functional food material having a known liver cell protection and liver damage prevention effect is extremely limited, and according to the recent health-oriented recent trend, the need for the discovery of the active substance having the above-mentioned efficacy from the food material has emerged.
또한, 아직까지 불미나리의 간세포 보호 및 간 손상 예방의 기능을 가진 활성 성분이 밝혀진바 없으며, 이 활성성분의 기능을 밝혀 음료류 등 기능성 건강지향 식품소재로 이용된 바도 없고, 또한 공개된 바도 없다.In addition, the active ingredient has not yet been found to function to protect the liver cells and prevent liver damage of the radish, has not been used as a functional health-oriented food material such as beverages, and has not been disclosed.
본 발명의 상기와 같은 종래기술의 문제점을 해결하기 위한 것으로, 본 발명의 하나의 목적은 불미나리로부터 간세포보호 및 간 손상 예방 효능을 갖는 카페익산을 추출하는 방법을 제공하는 것이다. In order to solve the above problems of the prior art of the present invention, one object of the present invention is to provide a method for extracting caffeic acid having hepatocellular protection and liver damage prevention effect from the radish.
본 발명의 다른 목적은 상기의 방법에 의해 제조된 불미나리 유래 카페익산을 포함하는 간 세포 보호 및 간 손상 예방 생리활성을 갖는 기능성 건강지향식품을 제공하는 것이다.It is another object of the present invention to provide a functional health-oriented food having hepatic cell protection and hepatic damage prevention physiological activity, which includes the fluoride-derived caffeic acid prepared by the above method.
상기한 목적을 달성하기 위하여, 본 발명은 간 보호 작용이 우수하며, 안전성이 뛰어난 불미나리(Oenanthe javanica DC) 유래 카페익산을 추출하는 방법을 제공한다.In order to achieve the above object, the present invention has excellent liver protection action, excellent safety ( Oenanthe javanica DC) provides a method for extracting caffeic acid derived from.
본 발명은 상기 추출방법에 의해 불미나리를 추출한 것임을 특징으로 하는 불미나리(Oenanthe javanica DC) 추출물을 제공한다.The present invention is characterized by extracting the firewood by the extraction method ( Oenanthe javanica DC) extract.
본 발명은 불미나리(Oenanthe javanica DC) 유래 카페익산을 포함하는 기능성 건강식품을 제공한다.The present invention is Oenanthe javanica DC) provides functional health foods containing caffeic acid.
본 발명에 의한 불미나리(Oenanthe javanica DC) 유래 카페익산은 간 세포 보호 및 간 손상 예방 효능이 있으므로, 이를 함유하는 분말류, 음료류, 가공 식품류 등과 같은 기능성 건강지향식품의 제조에 유용하게 사용할 수 있다. Oenanthe according to the present invention Caffeic acid derived from javanica DC) is effective in the production of functional health-oriented foods, such as powders, beverages, processed foods, etc., because the caffeic acid derived from liver cells protects and prevents liver damage.
본 발명은 간 보호 작용이 우수하며, 안전성이 뛰어난 불미나리(Oenanthe javanica DC)의 카페익산을 추출하여 제공한다.The present invention provides an excellent hepatoprotective action, and extracts the caffeic acid of Oenanthe javanica DC excellent safety.
본 발명은 불미나리(Oenanthe javanica DC)를 에탄올로 1차 환류추출하고, 에틸아세테이트로 2차 추출하여 얻어진 분획물을 분석용 얇은막 크로마토그래피와 역상 고성능 액체크로마티그래피를 수행하여 카페익산에 해당하는 구획을 확인하고, 수집용 얇은막 크로마토그래피 및 역상 고성능 액체크로마토크래피를 수행하여 카페익산을 추출하는 것을 특징으로 한다.In the present invention, the fraction obtained by primary reflux extraction of Oenanthe javanica DC with ethanol and secondary extraction with ethyl acetate is subjected to analytical thin layer chromatography and reverse phase high performance liquid chromatography to obtain a compartment corresponding to caffeic acid. It is characterized in that the extraction of caffeic acid by performing collecting thin layer chromatography and reverse phase high performance liquid chromatography.
먼저 카페익산을 추출하기 위하여, 건조한 불미나리의 잎과 줄기를 분말화 한 후, 불미나리 분말 중량 대비 10 내지 20배 부피의 80% 에탄올을 첨가하고, 200 내지 300℃에서 2 내지 4시간 교반하여 추출하는 것이 바람직하다. 상기 추출액을 여과지를 이용하여 상등액을 수득하고, 회전증발기를 이용하여 감압농축, 건조하여 분말 형태의 불미나리 1차 추출물을 얻는 것이 바람직하다. First, in order to extract the caffeic acid, the leaves and stems of dry radish are powdered, and then 80% ethanol is added in a volume of 10 to 20 times the weight of the radish powder, and extracted by stirring at 200 to 300 ° C. for 2 to 4 hours. It is preferable. The extract is preferably filtered to obtain a supernatant, concentrated under reduced pressure using a rotary evaporator, and dried to obtain a powdery radish primary extract.
상기 불미나리 1차 추출물에 5%(W/V) 증류수를 첨가하고 1 ~ 2 부피의 핵산을 섞어 핵산에 용출된 핵산 분획물을 제거하고 남은 수층에 1 ~ 2 부피의 클로로포름을 섞어 클로로포름에 용출된 클로로포름 분획물을 제거하고, 남은 수층에 1 ~ 2 부피의 에틸아세테이트를 섞어 에틸아세테이트에 용출된 에틸아세테이트 분획물 을 수층과 분리하여, 0.3㎛ 여과지로 여과한 후 감압농축하여 불미나리 2차 추출물을 얻는 것이 바람직하다.5% (W / V) distilled water was added to the primary extract of the parsley, 1 to 2 volumes of nucleic acid was mixed to remove the nucleic acid fractions eluted to the nucleic acid, and 1 to 2 volumes of chloroform was mixed with the remaining aqueous layer to chloroform eluted with chloroform. It is preferable to remove the fractions, mix 1 to 2 volumes of ethyl acetate in the remaining aqueous layer, separate the ethyl acetate fraction eluted from ethyl acetate from the aqueous layer, filter with 0.3 µm filter paper, and concentrate under reduced pressure to obtain a fluoride secondary extract. .
또한, 상기 불미나리 2차 추출물을 메탄올로 녹여 분석용 얇은 막 크로마토그래피와 역상 고성능 액체크로마토그래피를 수행하여 불미나리 유래 카페익산의 확인하는 것이 바람직하다.In addition, it is preferable to identify the fluoride-derived caffeic acid by dissolving the bulgeul secondary extract with methanol, performing analytical thin layer chromatography and reversed phase high performance liquid chromatography.
상기에서 규명한 불미나리 유래 카페익산을 수집용 역상 고성능 액체크로마토그래피방법을 이용하여 분리된 수집액을 감압하고 증발 건조시켜 수득하는 것이 바람직하다.It is preferable that the collected liquid is separated by depressurizing and evaporating to dryness using the above-mentioned reverse phase high performance liquid chromatography method.
본 발명은 상기 추출방법에 의해 불미나리를 추출한 것임을 특징으로 하는 불미나리 추출물을 제공한다.The present invention provides a firewood extract, characterized in that by extracting the firewood by the extraction method.
본 발명은 불미나리 유래 카페익산이 간세포 보호 및 간 손상 예방 효과를 나타내는지 조사하기 위하여 세포 실험과 동물 실험을 수행하였다. 본 발명의 바람직한 실시예에 의하면, 본 발명의 불미나리 유래 카페익산은 과산화수소에 의해 유도된 간세포 손상을 보호하며, 사염화탄소에 의한 간 손상을 예방하는 효과가 있음을 확인할 수 있다.In the present invention, cell experiments and animal experiments were conducted to investigate whether or not feminine derived caffeic acid exhibited hepatocellular protection and liver damage prevention effects. According to a preferred embodiment of the present invention, it can be seen that the fluoride-derived caffeic acid of the present invention protects liver cell damage induced by hydrogen peroxide and prevents liver damage caused by carbon tetrachloride.
또한, 본 발명은 불미나리 유래 카페익산을 함유하는 기능성 건강지향식품의 소재로 활용 할 수 있다. In addition, the present invention can be utilized as a material of functional health-oriented foods containing a calculus-derived caffeic acid.
상기 기능성 건강지향식품은 간세포손상 보호 및 간 손상 예방 등의 기능을 가지며, 음료, 환, 과립, 가공 식품류 등을 그 예로 들 수 있으나, 이에 한정되는 것은 아니다. The functional health-oriented food has functions such as protecting liver cells and preventing liver damage, and examples thereof include beverages, pills, granules, processed foods, and the like, but are not limited thereto.
본 발명에서 카페익산을 함유하는 음료는 정백당, 액사과당, 구연산, 구연산나트륨, 말토덱스트린, 젖산칼슘, 염화나트륨, 염화칼륨, 염화마그네슘, 화이트클라우디 및 이산화탄소 중에서 선택된 어느 하나 이상을 함유하는 것이 바람직하다.In the present invention, the beverage containing caffeic acid preferably contains any one or more selected from white sugar, liquid fructose, citric acid, sodium citrate, maltodextrin, calcium lactate, sodium chloride, potassium chloride, magnesium chloride, white claudi and carbon dioxide.
상기 카페익산을 함유하는 음료는 100㎖당 5~100㎎의 카페익산을 함유하는 것이 바람직하다. The beverage containing caffeic acid preferably contains 5-100 mg of caffeic acid per 100 ml.
또한, 상기 기능성 건강식품은 불미나리 유래 카페익산을 하루에 10~40㎎/㎏, 바람직하게는 30~40㎎/㎏을 1회 또는 수회로 나누어 먹을 수 있도록 통상의 방법으로 제조할 수 있다. 그러나 그 실제 함유량은 건강식품의 유형 및 체중 등 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야하며, 따라서 상기 함유량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.In addition, the functional health food can be prepared by a conventional method to eat 10-40 mg / kg, preferably 30 to 40 mg / kg, once or several times a day from the fire radish-derived caffeic acid. However, it should be understood that the actual content should be determined in view of various related factors such as the type and weight of the health food, and thus the content does not limit the scope of the present invention in any aspect.
이하 실시예에 의하여 본 발명을 상세히 설명하고자 한다. 다만 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 실시예에 한정되는 것은 아니다.By the following examples will be described in detail the present invention. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the examples.
[실시예 1] 불미나리 유래 카페익산의 제조Example 1 Preparation of Caffeic Acid Derived from Flakes
불미나리(Oenanthe javanica DC)는 화순 소재 (주) 한우물에서 공급받아 본 발명에 사용하였다. 건조, 분말화한 불미나리 50g에 20배 부피의 에탄올을 첨가하여 250℃에서 3시간 동안 교반 후, 0.3㎛의 필터를 이용하여 여과한 다음, 상등액 을 45℃에서 30분 동안 감압농축하여 10-4 torr, 72시간의 조건으로 동결건조하여 불미나리 1차 추출물 분말을 얻었다. Oenanthe javanica DC was supplied from Hanwoo Co., Ltd., Hwasun, and used in the present invention. 50 g of dried and powdered buttercups were added with 20-fold volume of ethanol, stirred at 250 ° C. for 3 hours, filtered using a 0.3 μm filter, and the supernatant was concentrated under reduced pressure at 45 ° C. for 30 minutes to obtain 10 −4. Torr, lyophilized under a condition of 72 hours to obtain a powder of the bulrush primary extract.
상기 불미나리 1차 추출물 10g에 200㎖의 증류수를 첨가하여 1차 추출물 분말을 완전히 풀어준 후, 200㎖의 핵산을 첨가하여 혼합한 후 분획하였다. 분획의 핵산층에 용출된 핵산분획물을 제거하고 같은 방법으로 1회 더 시행하였다. 핵산분획물과 분리된 수층에 200㎖의 클로로포름을 첨가하여 혼합한 후 분획하였다. 분획의 클로로포름에 용출된 클로로포름분획물을 제거하고 같은 방법으로 1회 더 시행하였다. 클로로포름분획물과 분리된 수층에 200㎖의 에틸아세테이트를 첨가하여 혼합한 후 분획하였다. 이때 수층과 분리된 에틸아세테이트분획물을 수집용기에 수집하고 같은 방법으로 1회 더 시행하여 같은 수집용기에 수집한 후 0.3㎛ 여과지로 여과한 후 감압농축 및 질소가스 용매 증발법을 이용하여 불미나리 2차 추출물(에틸아세테이트 분획물)을 수득하였다. 200 ml of distilled water was added to 10 g of the primary extract of Burberry to completely dissolve the primary extract powder, and 200 ml of nucleic acid was added thereto to mix and fractionated. The nucleic acid fraction eluted in the nucleic acid layer of the fraction was removed and performed once more in the same manner. 200 ml of chloroform was added to the separated aqueous layer and the nucleic acid fractions were mixed and fractionated. The chloroform fraction eluted in the chloroform of the fraction was removed and subjected to the same method once more. To the aqueous layer separated from the chloroform fractions, 200 ml of ethyl acetate was added, mixed and fractionated. At this time, the ethyl acetate fraction separated from the aqueous layer was collected in a collection container, and once more carried out in the same manner, collected in the same collection container, filtered through a 0.3 μm filter paper, and then filtered through a 0.3 μm filter solution and a nitrogen gas solvent evaporation method. An extract (ethyl acetate fraction) was obtained.
상기 2차 추출물은 다시 메탄올에 녹여 분석용 얇은 막 크로마토그래피(에틸아세테이트:액산: 물:개미산=40:20:5:5(v/v/v/v)와 역상 고성능액체크로마토그래피(70% 메탄올, 0.1% phosphoric acid)를 불미나리의 단일획분을 분리하고 13C/1H-NMR로 구조분석하여 카페익산으로 규명하였다. 수집용 얇은 막 크로마토그래피와 역상 고압액체크로마토그래피를 이용하여 규명된 불미나리 유래 카페익산을 수집하였다.The secondary extract was again dissolved in methanol for thin layer chromatography for analysis (ethyl acetate: liquid acid: water: formic acid = 40:20: 5: 5 (v / v / v / v)) and reversed phase high performance liquid chromatography (70%). Methanol, 0.1% phosphoric acid) was isolated from single fractions of vulgaris and identified as caffeic acid by structural analysis by 13 C / 1 H-NMR Fluorides were identified by using thin membrane chromatography for collection and reversed-phase high-pressure liquid chromatography. The derived caffeic acid was collected.
[실시예 2] 불미나리 유래 카페익산의 간세포 보호 효과 측정Example 2 Measurement of Hepatocellular Protective Effect of Flax-Derived Caffeic Acid
상기 실시예 1에서 수집 제조된 카페익산의 간세포 보호 효과를 확인하기 위하여 HepG 2 세포주에 불미나리 유래 카페익산을 처리하여 배양한 후, 과산화수소를 이용하여 간세포 손상을 유발한 뒤 XTT 방법을 이용하여 카페익산의 간세포 보호 효과를 측정하였다.In order to confirm the hepatocyte protective effect of the caffeic acid collected and collected in Example 1, the
HepG 2 세포주를 24 well 배양용기에 80% confluence한 상태로 준비하여 DMEM 배양액으로 37℃ 배양기에서 배양한 후, 24시간 동안 불미나리 유래 카페익산을 10, 20, 30, 40, 50 ㎍/㎖ 농도로 처리하여 배양한다. 배양액을 제거한 후, 2mM 과산화수소를 이용하여 간세포의 손상을 유발하고, XTT 세포 생존율 평가 방법(Rochem N.W. et al., J. Immunol. Methods 142 : 257-265, 1991)을 이용하여 살아있는 간세포에서 형성된 포마잔을 450㎚ 파장에서 흡광도를 측정하여 값을 구하였다.
도 2에 나타낸 바와 같이 불미나리 유래 카페익산은 과산화수소로 유발된 간세포 손상을 20㎍/㎖ 이상부터 보호하는 것을 확인할 수 있었다. As shown in FIG. 2, it was confirmed that fluoride-derived caffeic acid protects hepatocyte damage induced by hydrogen peroxide from 20 μg / ml or more.
[실시예 3] 불미나리 유래 카페익산의 사염화탄소에 의한 간손상 예방 측정Example 3 Measurement of Prevention of Liver Damage by Carbon Tetrachloride of Caffeic Acid Derived from Flakes
불미나리 유래 카페익산의 간 손상 보호 효과를 측정하기 위하여 웅성 흰쥐에 실시예 1에서 제조한 불미나리 유래 카페익산을 경구 투여하고, 사염화탄소에 의해 간 손상을 유도한 후, 혈청 중 GOT(Glutamic Oxalacetic Transaminase)와 GPT(Glutamic Pyruvic Transaminase) 양을 측정하였다. 또한, 각 투여군에 따른 간 조직 박편을 대조군과 비교 평가하였다.In order to measure the protective effect of hepatic decay-derived caffeic acid, male oral rats were orally administered with the heparin-derived caffeic acid prepared in Example 1, induce liver damage by carbon tetrachloride, and GOT (Glutamic Oxalacetic Transaminase) in serum. GPT (Glutamic Pyruvic Transaminase) amount was measured. In addition, liver tissue flakes according to each administration group were evaluated in comparison with the control group.
500~600g의 웅성 흰쥐를 1주 동안 실험실 환경에 적응시키고 사료와 물을 충분히 공급하면서 사육하였다. 총 24마리의 웅성 흰쥐를 각 6마리씩 4군으로 나누고 <표 1>과 같이 체중의 1% 부피의 량을 경구투여 하였다. 15일째에 사염화탄소를 20% 농도로 옥수수기름에 녹여, 체중의 1% 부피의 량을 1회 경구 투여하고, 24시간 후 해부하여 혈청과 간 조직을 수득하여 실험 전까지 혈청은 -20℃에서 보관하였다. 각 군의 혈청을 GOT, GPT Kit(아산제약)를 이용하여 평가하고 1군에 비하여 2군이 통계적으로 유의하게 높아졌고, 불미나리 유래 카페익산을 투여한 3군과 4군에서 1군과 유사한 수준을 보임으로써 간 손상으로 인해 높아지는 두 가지 효소 GOT, GPT의 결과를 평가하면 간 손상을 예방하는 효과가 있음을 확인하였다<표 2>. 500-600 g of male rats were kept for 1 week in the laboratory environment and fed with sufficient feed and water. A total of 24 male rats were divided into 4 groups of 6 rats each, and 1% volume of body weight was orally administered as shown in <Table 1>. On day 15, carbon tetrachloride was dissolved in corn oil at a concentration of 20%, 1% volume of body weight was orally administered once, dissected after 24 hours to obtain serum and liver tissue, and the serum was stored at -20 ° C until the experiment. . Serum of each group was evaluated using GOT and GPT Kit (Asan Pharmaceutical), and
또한 각 군의 조직박편을 비교한 결과 사염화탄소에 유도된 간 손상이 미리 투여된 카페익산(40㎎/㎏/day)에 의해 예방하는 효과가 있음을 확인하였다(도 3a, 도 3b).In addition, as a result of comparing the tissue flakes of each group, it was confirmed that the liver damage induced by carbon tetrachloride was prevented by the previously administered caffeic acid (40 mg / kg / day) (FIGS. 3A and 3B).
<표 1> 불미나리에서 분리한 카페익산의 간 손상 예방 평가를 위한 실험동물 분류표<Table 1> Classification of laboratory animals for the prevention of liver damage of caffeic acid isolated from firewood
<표 2> 불미나리에서 분리한 카페익산의 간손상 예방 효능 도표<Table 2> Effect of Caffeic Acid Isolated from Flame Butter on Preventing Liver Damage
a, b 같은 문자는 95% 신뢰 수준에서 통계적 유의차를 보이지 않은 경우Characters such as a and b do not show statistical significance at 95% confidence
[실시예 4] 불미나리 유래 카페익산을 함유하는 기능성 음료의 제조 Example 4 Preparation of Functional Drink Containing Flaky Derived Caffeic Acid
본 발명은 상기 실시예 1에서 제조한 불미나리(Oenanthe javanica DC) 에탄올 추출물 또는 불미나리 유래 카페익산을 함유하는 간세포 보호 및 간 손상 예방 생리활성을 갖는 기능성 음료를 제조하였다.The present invention is prepared in Example 1 Buttercup ( Oenanthe javanica DC) A functional beverage having a physiological activity of protecting liver cells and preventing liver damage, containing ethanol extract or flax-derived caffeic acid, was prepared.
(1) 정제수 100㎖에 불미나리 에탄올 추출물을 20㎎, 50㎎ 및 100㎎을 각각 혼합하고, 정백당 100mg, 액상과당 10mg, 구연산 1.0mg, 구연산나트륨 0.3mg를 혼합한 후, 3%의 이산화탄소를 첨가하여 불미나리 에탄올 추출물을 함유하는 탄산음료를 제조하였다.(1) 100 mg of purified
(2) 정제수 180㎖에 불미나리 에탄올 추출물을 20㎎, 50㎎ 및 100㎎을 각각 혼합하고, 정백당 5 mg, 말토덱스트린 100 mg, 무수구연산 0.1 mg, 무수구연산나트륨 0.03 mg, 젖산칼슘 0.03 mg, 염화나트륨 0.01 mg, 염화칼륨 0.01 mg, 염화마그네슘 0.001 mg, 화이트클라우디 0.02 mg을 첨가한 불미나리 에탄올추출물을 함유하는 이온음료를 제조하였다.(2) 180 mg of purified water was mixed with 20 mg, 50 mg, and 100 mg of ethanol extract, respectively, 5 mg per white, maltodextrin 100 mg, 0.1 mg anhydrous citric acid, 0.03 mg anhydrous sodium citrate, 0.03 mg calcium lactate, sodium chloride An ion beverage containing flaky ethanol extract added with 0.01 mg, 0.01 mg potassium chloride, 0.001 mg magnesium chloride, and 0.02 mg white clady was prepared.
(3) 정제수 100㎖에 불미나리 에탄올 추출물을 20㎎, 50㎎ 및 100㎎을 각각 혼합하고, 정백당 100 mg, 액상과당 10 mg, 구연산 1.0 mg, 구연산나트륨 0.3 mg를 혼합한 후, 3%의 이산화탄소를 첨가하여 불미나리 유래 카페익산을 함유하는 탄산음료를 제조하였다. (3) 100 mg of purified
(4) 정제수 180㎖에 불미나리 유래 카페익산을 10㎎ 및 40㎎을 각각 혼합하고, 정백당 5 mg, 말토덱스트린 100 mg, 무수구연산 0.1 mg, 무수구연산나트륨 0.03 mg, 젖산칼슘 0.03 mg, 염화나트륨 0.01 mg, 염화칼륨 0.01 mg, 염화마그네슘 0.001 mg, 화이트클라우디 0.02 mg을 첨가한 불미나리 에탄올추출물을 함유하는 이온음료를 제조하였다.(4) 180 mg of purified water was mixed with 10 mg and 40 mg of flax-derived caffeic acid, respectively, 5 mg per white, maltodextrin 100 mg, 0.1 mg anhydrous citric acid, 0.03 mg anhydrous sodium citrate, 0.03 mg calcium lactate, 0.01 mg sodium chloride. , Ion chloride containing 0.01 mg of potassium chloride, 0.001 mg of magnesium chloride, and 0.02 mg of white Claudia was prepared.
상술한 바와 같이, 본 발명의 바람직한 실시예를 참조하여 설명하였지만 해당 기술 분야에서 숙련된 당업자라면 하기의 특허청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.As described above, those skilled in the art have been described with reference to the preferred embodiments of the present invention, various modifications and changes of the present invention without departing from the spirit and scope of the present invention as set forth in the claims below. It will be appreciated that it can be changed.
도 1은 본 발명에 의한 불미나리 에탄올추출물로부터 분리한 카페익산의 역상 고성능 액체크로마토그래피 그래프를 나타낸 것이다.Figure 1 shows a reverse phase high performance liquid chromatography graph of caffeic acid isolated from fluoride ethanol extract according to the present invention.
도 2는 본 발명에 의한 불미나리에서 분리한 카페익산의 간세포 보호 효능을 그래프로 나타낸 것이다.Figure 2 is a graph showing the hepatocellular protective effect of the caffeic acid isolated from the radish according to the present invention.
CON : 과산화수소 무처리군, CON: no hydrogen peroxide treatment group,
2 mM HPO : 과산화수소 처리군,2 mM HPO: hydrogen peroxide treatment group,
CA 10 ~ CA 50 : 불미나리유래 카페익산 10㎍/㎖, 20㎍/㎖, 30㎍/㎖, 40㎍/㎖, 50㎍/㎖ 처리군,
* 과산화수소 처리군과 비교하여 95% 신뢰구간에서 통계적 유의차가 있는 경우> * Statistically significant difference in 95% confidence interval compared with hydrogen peroxide treatment group>
도 3a는 본 발명에 의한 불미나리에서 분리한 카페익산의 투여에 의한 간 손상 예방을 확인하기 위한 조직박편의 사진을 나타낸 것이다.Figure 3a shows a photograph of the tissue flakes for confirming the prevention of liver damage by administration of caffeic acid isolated from the bulge according to the present invention.
<실험군> Experimental group
A: 옥수수기름 투여군(14일간) + 생리식염수A: corn oil group (14 days) + saline solution
B: 옥수수기름 투여군(14일간) + 생리식염수에 20% 사염화탄소를 제조하여 투여한 군(실험마지막 날)B: Corn oil-treated group (14 days) + 20% carbon tetrachloride prepared and administered to physiological saline (the last day of the experiment)
C: 옥수수기름에 불미나리 유래 카페익산을 40㎎/㎏/day 녹여 투여한 군(14일간) + 생리식염수에 20% 사염화탄소를 제조하여 투여한 군(실험마지막 날)C: A group in which 40 mg / kg / day of disintegrated caffeic acid in corn oil was administered (14 days) + 20% carbon tetrachloride was prepared and administered in physiological saline (the last day of the experiment).
도 3b는 본 발명에 의한 불미나리에서 분리한 카페익산의 투여에 의한 간손상 예방 조직박편에 대한 평가를 도표로 나타낸 것이다. Figure 3b is a chart showing the evaluation of the liver tissue preventive tissue flakes by administration of the caffeic acid isolated from the bulge according to the present invention.
<다음에 따라 조직손상의 등급을 결정한다> <Determine the level of tissue damage according to the following>
1) 정상(-), 가벼움(+), 중증도(++), 심각함(+++)1) Normal (-), Light (+), Severe (++), Severe (+++)
2) 1 ~ 6 : 각 군이 포함하는 개체의 수>2) 1 ~ 6: number of individuals in each group>
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080034386A KR100977583B1 (en) | 2008-04-14 | 2008-04-14 | Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080034386A KR100977583B1 (en) | 2008-04-14 | 2008-04-14 | Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090109007A true KR20090109007A (en) | 2009-10-19 |
KR100977583B1 KR100977583B1 (en) | 2010-08-24 |
Family
ID=41552346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080034386A KR100977583B1 (en) | 2008-04-14 | 2008-04-14 | Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100977583B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190052724A (en) | 2017-10-27 | 2019-05-17 | 대구한의대학교산학협력단 | Composition comprising extract of Litsea japonica (Thunb.) Juss fruit or flesh for protecting liver |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913726A (en) | 1982-07-13 | 1984-01-24 | Osaka Chem Lab | Food composed mainly of concentrated dropwort |
KR100339154B1 (en) * | 1994-12-28 | 2002-12-11 | 주식회사 엘지씨아이 | Method of extraction of caffeic acid from oenanthe javanica |
KR970009810A (en) * | 1995-08-29 | 1997-03-27 | 박종철 | Hepatotoxic detoxifiers from buttercup |
KR20080035853A (en) * | 2006-10-20 | 2008-04-24 | 주식회사 경인제약 | A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same |
-
2008
- 2008-04-14 KR KR1020080034386A patent/KR100977583B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190052724A (en) | 2017-10-27 | 2019-05-17 | 대구한의대학교산학협력단 | Composition comprising extract of Litsea japonica (Thunb.) Juss fruit or flesh for protecting liver |
Also Published As
Publication number | Publication date |
---|---|
KR100977583B1 (en) | 2010-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shikov et al. | Medicinal plants of the Russian Pharmacopoeia; their history and applications | |
US6440448B1 (en) | Food supplement/herbal composition for health enhancement | |
Bachar et al. | Antioxidant and hepatoprotective activities of ethanolic extracts of leaves of Premna esculenta Roxb. against carbon tetrachloride-induced liver damage in rats | |
Parthasarathy et al. | Antidiabetic activity of Thespesia Populnea bark and leaf extract against streptozotocin induced diabetic rats | |
Khan et al. | Antiobesity, hypolipidemic, antioxidant and hepatoprotective effects of Achyranthes aspera seed saponins in high cholesterol fed albino rats | |
Fugh-Berman | The 5-minute herb and dietary supplement consult | |
Perera et al. | Perspectives on geraniin, a multifunctional natural bioactive compound | |
CN109568538B (en) | Composition for relieving hangover comprising Silybum marianum, Curcuma longa, Glycyrrhiza glabra and Cassia tora seed | |
JP2006016312A (en) | Fat-metabolism improving composition | |
EP1843774B1 (en) | Pulsatilla spp. extracts effective in brain function | |
Gupta et al. | PHCOG MAG.: Plant review Withania somnifera (Ashwagandha): A review | |
KR20170054882A (en) | A pharmaceutical composition comprising cirsium japonicum | |
KR100977583B1 (en) | Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same | |
Hassan et al. | Wheat Grass (Triticum aestivum L.) Benefits Health in a Pandemic Scenario | |
KR101470603B1 (en) | Manufacturing method of herbextract for removing harmful elements caused by smoking | |
Devi et al. | Antihyperglycemic effect of aqueous and ethanol extract of aerial part of Osbeckia nepalensis hook in alloxan induced diabetic rats | |
Mohammed et al. | Evaluation of the effect of aqueous leaf extract of jute mallow corchorus olitorius on some biochemical parameters in alloxan-induced diabetic rats | |
Jayachandra et al. | Hepatoprotective effect of Aegle Marmelos (L.) Corr. Leaf powder (Crude) against carbon tetrachloride-induced hepatic damage in albino rats | |
Tetrachloride-Induced et al. | The protective effect of Morus alba and Calendula officinalis plant extracts on carbon tetrachloride-induced hepatotoxicity in isolated rat hepatocytes | |
KR100315001B1 (en) | Herbal Medicine for the Treatment of Diabetes Mellitus Containing Enteric Bellflower Extract | |
KR101165712B1 (en) | Composition for the anti-inflammatory and analgesia comprising extract of propolis and Sophora japonica complex containing flavonoid | |
KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
Moustafa et al. | Protective effect of strawberry leaves against nephrotoxicity of male rats | |
EP1207894B1 (en) | Use of a synergistic composition for the manufacture of a medicament for the treatment of liver associated ailments | |
Lim et al. | Phyllanthus emblica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130814 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140710 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150805 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |